Published online before print June 27, 2005, doi: 10.1161/CIRCULATIONAHA.104.527549
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
(Circulation. 2005;112:39-47.)
© 2005 American Heart Association, Inc.
Health Services and Outcomes Research |
Adoption of Spironolactone Therapy for Older Patients With Heart Failure and Left Ventricular Systolic Dysfunction in the United States, 1998–2001
From the Division of Cardiology, Department of Medicine, Denver Health Medical Center (F.A.M., E.P.H.); and the Division of Cardiology, Department of Medicine (F.A.M., E.P.H.), and the Division of Geriatric Medicine, Department of Medicine (F.A.M.), University of Colorado Health Sciences Center, Denver, Colo; the Colorado Foundation for Medical Care (F.A.M., E.P.H., H.M.K.), Aurora, Colo; the Colorado Health Outcomes Program (F.A.M.), Aurora, Colo; the Section of General Internal Medicine, Department of Medicine (C.P.G.); the Section of Cardiovascular Medicine, Department of Medicine (S.S.R., Y.W., J.M.F., H.M.K.), and the Section of Health Policy and Administration, Department of Epidemiology and Public Health (H.M.K.), Yale University School of Medicine, New Haven, Conn; the Center for Outcomes Research and Evaluation (H.M.K., C.G.), Yale–New Haven Hospital, New Haven, Conn; and the Section of Cardiology, Department of Medicine, West Haven Veteran’s Administration Medical Center (J.M.F.), West Haven, Conn.
Correspondence to Frederick A. Masoudi, MD, MSPH, Division of Cardiology, MC 0960 Denver Health Medical Center, 777 Bannock St, Denver, CO 80204. E-mail fred.masoudi{at}uchsc.edu
Received December 4, 2004; revision received March 1, 2005; accepted March 28, 2005.
Background— Concerns have been raised about the appropriateness of spironolactone use in some patients with heart failure. We studied the adoption of spironolactone therapy after publication of the Randomized Aldactone Evaluation Study (RALES) in national cohorts of older patients hospitalized for heart failure.
Methods and Results— This is a study of serial cross-sectional samples of Medicare beneficiaries 
65 years old discharged after hospitalization for the primary diagnosis of heart failure and with left ventricular systolic dysfunction. The first sample was discharged before (April 1998 to March 1999, n=9758) and the second sample after (July 2000 to June 2001, n=9468) publication of RALES in September 1999. We assessed spironolactone prescriptions at hospital discharge in patient groups defined by enrollment criteria for the trial. Using multivariable logistic regression, we identified factors independently associated with prescriptions not meeting these criteria. Spironolactone use increased >7-fold (3.0% to 21.3% P<0.0001) after RALES. Of patients meeting enrollment criteria, 24.1% received spironolactone, as compared with 17.4% of those not meeting the criteria. Of all prescriptions after RALES, 30.9% were provided to patients not meeting enrollment criteria. Spironolactone was prescribed to 22.8% of patients with a serum potassium value 5.0 mmol/L, to 14.1% with a serum creatinine value 2.5 mg/dL, and to 17.3% with severe renal dysfunction (estimated glomerular filtration rate <30 mL · min–1 · 1.73 m–2). In multivariable analyses, factors associated with prescriptions not meeting enrollment criteria included advanced age, noncardiovascular comorbidities, discharge to skilled nursing facilities, and care provided by physicians without board certification.
Conclusions— Spironolactone prescriptions increased markedly after the publication of RALES, and many treated patients were at risk for hyperkalemia. Simultaneously, many patients who might have benefited were not treated. These findings demonstrate the importance of balancing efforts to enhance use among appropriate patients and minimizing use in patients at risk for adverse events.
Key Words: heart failure • aging • aldosterone antagonists • potassium
This article has been cited by other articles:
 |
|
 |
|
  P. M. Ho, P. N. Peterson, and F. A. Masoudi Evaluating the Evidence: Is There a Rigid Hierarchy? Circulation, October 14, 2008; 118(16): 1675 - 1684. [Full Text] [PDF]
|
|
|
|
|
|
F. A. McAlister Cardiac Resynchronization Therapy for Heart Failure: A Hammer in Search of Nails Circulation, August 26, 2008; 118(9): 901 - 903. [Full Text] [PDF]
|
|
|
|
 |
|
 E. S. Holmboe, R. Lipner, and A. Greiner Assessing Quality of Care: Knowledge Matters JAMA, January 23, 2008; 299(3): 338 - 340. [Full Text] [PDF]
|
|
|
|
|
|
F. A. Masoudi Measuring the Quality of Primary PCI for ST-Segment Elevation Myocardial Infarction: Time for Balance JAMA, December 19, 2007; 298(23): 2790 - 2791. [Full Text] [PDF]
|
|
|
|
 |
|
 H. M. Krumholz and F. A. Masoudi The Year in Epidemiology, Health Services Research, and Outcomes Research J. Am. Coll. Cardiol., December 4, 2007; 50(23): 2254 - 2262. [Full Text] [PDF]
|
|
|
|
|
|
G. H. Gislason, J. N. Rasmussen, S. Z. Abildstrom, T. K. Schramm, M. L. Hansen, P. Buch, R. Sorensen, F. Folke, N. Gadsboll, S. Rasmussen, et al. Persistent Use of Evidence-Based Pharmacotherapy in Heart Failure Is Associated With Improved Outcomes Circulation, August 14, 2007; 116(7): 737 - 744. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 C. C Lang and D. M Mancini Non-cardiac comorbidities in chronic heart failure Heart, June 1, 2007; 93(6): 665 - 671. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
H. M. Krumholz and F. A. Masoudi The Year in Epidemiology, Health Services Research, and Outcomes Research J. Am. Coll. Cardiol., November 7, 2006; 48(9): 1886 - 1895. [Full Text] [PDF]
|
|
|
|
 |
|
 F. A. Masoudi, C. A. Baillie, Y. Wang, W. D. Bradford, J. F. Steiner, E. P. Havranek, J. M. Foody, and H. M. Krumholz The Complexity and Cost of Drug Regimens of Older Patients Hospitalized With Heart Failure in the United States, 1998-2001 Arch Intern Med, October 10, 2005; 165(18): 2069 - 2076. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 How Is Spironolactone Being Used for Heart Failure in Practice? Journal Watch Cardiology, September 9, 2005; 2005(909): 1 - 1. [Full Text]
|
|